|
Mission
To
develop a multi-disciplinary approach to understand how myelin is formed, how
it is damaged in disease, and how it may be repaired.
Objectives
- To study myelin formation as
a source for strategies of myelin repair
- To study consequences of
myelin damage—common to all diseases of myelin—such as inflammation or
neurodegeneration which correlates best with disability (symptoms and problems
of daily living)
- To provide better cellular
and animal models (cell based assays, transgenic mice or fish) for identifying
mechanisms of disease
- To exploit models to perform
preclinical studies of therapies
- To translate the research of
HJKRI into prognostic, diagnostic and treatment applications in cooperation
with the University at Buffalo Department of Neurology and Hunter’s Hope
Foundation

What's going on in Basic Science?
The
laboratories of Drs. Feltri and Wrabetz, the first two basic science laboratories
of the HJKRI, are now fully equipped, functional and host a total of 20 people,
including undergraduate and graduate students, post doctoral fellows, senior
scientists, technicians and administrators.
In
Globoid Cell Leukodystrophy/Krabbe disease, deficiency of galactosylceramidase
(GALC) causes accumulation of psychosine, the toxic metabolite believed to
cause myelin breakdown (demyelination) by killing myelin-forming cells:
oligodendrocytes and Schwann cells. Psychosine
is also toxic for neurons [1], whose degeneration
ultimately causes the signs and symptoms of disease. Whether neurons suffer primarily or as
consequence of demyelination, and the exact mechanism of psychosine toxicity
are not understood. Other cell types
such as blood vessels and immune cells are also present in the nervous system
and they have been shown to potentially contribute to disease. For example,
macrophages, which in the Krabbe brain are the characteristic globoid cell that
gives the disease its name, are probably beneficial [2]. To design effective therapies requires
understanding which cells are targeted first by disease and in which cells it
is most important to restore GALC function. Dr. Daesung Shin in the HJKRI has
generated new GALC transgenes and Dr. Jeff Ceci is using them to generate new
mouse models of Krabbe disease in order to address these issues.
Clinical
studies such as those informed by the World Wide Registry of Krabbe patients
and the New York Newborn Screening Program have revealed that Krabbe disease is
not only a severe disease of infants, but also manifests with a wide spectrum of
severity that includes mild phenotypes with adult onset. The kind of DNA mutation that a patient
carries is not always predictive of outcome, and the reasons for such
variability—even within the same family—are unclear. This renders the doctor powerless in her or
his ability to predict the disease course, with profound implications for treatment
options. Understanding why some patients
develop milder forms of disease could also suggest a way to reduce disease
severity in all patients. To better
understand the effect of different mutations and to create new models of
disease with various severities, Dr. Daesung Shin has also generated five different
disease transgenes carrying GALC mutations characteristic of early or
late-onset Krabbe. These resulting transgenic mice should help us to understand
factors that determine the outcome and progression of disease, to design
rational and effective therapies, and to test them in preclinical trials.
Curing
Krabbe and other myelin diseases cannot occur without a better overall
understanding of myelin and neuronal function in the central and peripheral
nervous system. This is why the HJKRI
also fosters multidisciplinary research in all aspects of myelination,
including the study of oligodendrocyte, Schwann cell and neuronal
function. Active projects in the
Institute join the understanding of developmental myelination in normal
conditions to identification of pathological mechanisms in diseases of
peripheral myelin such as Charcot-Marie-Tooth and in syndromic
neuropathies. The HJKRI is actively
involved in building a critical mass of multidisciplinary investigators to
expand the work on myelination and its diseases, and will open calls for the
recruitment of 3-4 new primary investigators and their labs in 2012 and
2013.
1. Castelvetri, L.C., et al., Axonopathy is a compounding factor in the
pathogenesis of Krabbe disease. Acta neuropathologica, 2011. 122(1): p. 35-48.
2. Kondo, Y., et al., Macrophages counteract demyelination in a mouse model of globoid cell
leukodystrophy. J. Neurosci., 2011. 31(10):
p. 3610-24.
|
Meet the HJKRI Basic Science Team

Lawrence Wrabetz, MD Professor of Neurology, University at Buffalo Director, HJKRI Learn more about Dr. Wrabetz

M. Laura Feltri, MD Professor of Biochemistry, University at Buffalo Feltri Lab PI, HJKRI Learn more about Dr. Feltri

Caterina Berti Senior Research Scientist & Lab Manager Download PDF Bio
Daesung Shin Senior Scientist Download PDF Bio
Sophie Belin Post Doctoral Research Scientist Download PDF Bio
Yannick Poitelon Post Doctoral Research Scientist Download PDF Bio
Kathleen Catignas Doctoral Research Scientist Download PDF Bio
Monica Ghidinelli Doctoral Research Scientist Download PDF Bio
Marilena Palmisano Doctoral Research Scientist Download PDF Bio
Domenica Vizzuso Doctoral Research Scientist Download PDF Bio
Mariapaola Sidoli Doctoral Student Download PDF Bio
Jordan VerPlank Doctoral Research Scientist Download PDF Bio
Edward Hurley Research Technician Download PDF Bio
Courtney Williamson Research Technician Download PDF Bio
Nicole Little Laboratory Assistant Download PDF Bio
Maureen Milligan Research Administrator Download PDF Bio
Amanda Golner Office Assistant
Barbara Craft Administrative Assistant
|